Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-18
2009-12-08
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07629352
ABSTRACT:
This invention concerns the use of cyclopamine, a naturally occurring steroidal alkaloid known for over thirty years, for the treatment of psoriasis and achievement of rapid clearance of the psoriatic skin lesions together with the reversion of the histopathological signs of disease to normalcy with no detectable side effects. The cyclopamine-induced clearance of psoriatic lesions from the skin of patients is associated with the causation of cellular differentiation in lesional epidermis and with the rapid disappearance of CD4(+) lymphocytes and other inflammatory cells from lesional skin. Therapeutic compositions comprising of cyclopamine and a corticosteroid and/or the pre-treatment of lesions with a corticosteroid provide significantly further increased therapeutic effectiveness over the use of cyclopamine alone or a corticosteroid alone.
REFERENCES:
patent: 4370322 (1983-01-01), Busse et al.
patent: 6291516 (2001-09-01), Dudek et al.
patent: 6432970 (2002-08-01), Beachy et al.
patent: 6951839 (2005-10-01), Crompton
patent: 2002/0165221 (2002-11-01), Baxter et al.
patent: 2003/0119786 (2003-06-01), Keith et al.
patent: 2004/0072914 (2004-04-01), Tas et al.
patent: 2416731 (2003-01-01), None
patent: 9835020 (1998-08-01), None
patent: 9952534 (1999-10-01), None
patent: 0041545 (2000-07-01), None
patent: 0074706 (2000-12-01), None
patent: 0127135 (2001-04-01), None
patent: 0140438 (2001-06-01), None
patent: 0198344 (2001-12-01), None
patent: 0207702 (2002-01-01), None
patent: 0230462 (2002-04-01), None
patent: 02078703 (2002-10-01), None
patent: 02080952 (2002-10-01), None
van der Vleuten et al. Arch. Dermatol. Res., 1999, vol. 291, pp. 390-395.
Nilsson M et al, “Induction of Basal Cell Carcinomas and Trichoephitheliomas in Mice Overexpressing GLI-1”, Proc. Nat'l Acad. Sci. USA 2000; 97:3438-3443.
Suzuki, Hidekazu et al, “Down regulation of a morphogene(sonic hedgehog) gradient in the gastric epithelium ofHelicobacter pylori-infected Mongolian gerbils”, J. Pathol 2005: 206:187-197.
Sheng, Tao et al, “Activation of the hedgehog pathway in advanced prostate cancer”, Molecular Cancer 2004, 3:29.
Kumamoto, Hiroyuki et al, “Expression of Sonic Hedgehog (SHH) signaling molecules in ameloblastomas”, J. Oral Pathol Med (2004) 33: 185-190.
Xuan, Yan Hua et al, “Enhanced expression of hedgehog signaling molecules in squamous cell carcinoma of uterine cervix and it precursor lesions”, Modern Pathology (2006) 19, 1139-1147.
Hannun, Yusuf A., Blood: Apoptosis and the Dilemma of Cancer Chemotherapy, The Journal of The American Society of Hematology, vol. 89, No. 6, Mar. 15, 1997, pp. 1845-1853.
Bijlsma, Maarten F., et al :Repression of Smoothened by Patched-Dependetn (Pro-) Vitamin D3 Secrettion, PloS Biology, Aug. 2006, vol. 4, Issue 8, pp. 1397-1410.
Dahmane, N. et al, “Activation of the Trnascription of factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours”, Nature, vol. 389, Oct. 23, 1997, pp. 876-881.
Wicking, Carol et al “The Hedgehog Signalling Pathway in Tumorigenesis and Development”, Oncogene (1999), vol. 18, pp. 7844-7851.
Hahn, Heidi et al, “The Patched Signaling Pathway in Tumorigeneis and Development: Lessons from Animal Models”. J. Mol. Med (1999) vol. 77, pp. 459-468.
Kutney, James P. et al “Synthetic Studies in the veratrum Alkaloid Series II. The Total Synthesis of Verarine, Veratramine, Jervine and Veratrobasine”, Can. J. Chem. vol. 53, 1975, pp. 1796-1817.
Krauss. S., et al “A functionally conserved homolog of the drosophila segment polarity gene hh is expressed in tissues with polarizing activity in zebrafish embryos”,Cell vol. 75. pp. 1431-1444. Dec. 31, 1993.
Bellom, F. et al “Identification of Sonic hedgehog as a candidate gene responsible for holoprosencephaly”, Nature Genetics vol. 14, Nov. 1996, pp. 353-356.
Roessler, Erich et al, “Mutations in the human Sonic Hedge hog gene cause holoprosencephaly”, Nature Genetics, vol. 14, Nov. 1996, pp. 357-360.
Chiang, Chin, et al “Cyclopia and defective axial patterning in mice lacking Sonic Hedgehog gene function”, Nature, vol. 383, Oct. 3, 1996, pp. 407-413.
Ericson, Johan et al “Two critical periods of sonic hedgehog signaling required for the specifciation of motor neuron identity”, Cell. vol. 87, pp. 661-673, Nov. 15, 1996.
Chuang, Pao-Tien et al “Vertebrate hedgehog signalling modulated by induction of a hedgehog-binding protein” Nature vol. 397, Feb. 18, 1999, pp. 617-621.
Wang, Li Chun et al, “Conditional Disruption of Hedgehog Signaling Pathway Defines its Critical Role in Hair Development and Regeneration”, The Journal of Investigative Dermatology, vol. 114, No. 5, May 2000, pp. 901-908.
Williams, Kevin P. et al “Functional antagonists of sonic hedgehog reveal the importance of the N terminus for activity”. Journal of Cell Structure, vol. 112, (1999) pp. 4405-4414.
Bovenschen, H. J., et al, “Explorative immunohistochemical study of the evaluate the additional of a topical corticosteriod in the early phase of alefacept treatment for psoriasis”, Arc Dermatol Res. (2007), 298: 457-463.
Gniadecki, Robert, “Effects of 1,25-dihydroxyvitamin D3 and its 20-epi analogues (MC 1288, MC 1301, KH 1060), on clonal keratinocyte growth: evidence for differentiation of keratinocyte stem cells and analysis of the moduclatory effects of cytokines”. Britsh Journal of Pharmacology (1997) vol. 120, pp. 1119-1127.
Oro, Anthony E., et al “Basel Cell Carcinomas in Mice Overexpressing Sonic Hedgehog”, Science, vol. 276, May 2, 1997, pp. 817-821.
Hopyan Seva et al “Indian Hedgehog and Parathyroid hormone related protein signaling in cartilage tumors of bone.” Proceedings Of the American Association For Cancer Research Annual, No. 41, Mar. 2000 p. 206 XP008001019, 91st Annual Meeting of the American Association for Cancer Research, San Francisco, CA, US, April Jan. 05, 2000, Mar. 2000, ISSN< 0197-016X Abstract.
Chen et al “Analysis of the zebrafish smoothened mutant reveals conserved and divergent functions of hedgehog activity”, Development 128, 2385-2396 (2001).
Vorechovsky, Igor et al, “Trichoepitheliomas Contain Somatic Mutations in the Overexpressed PTCH Gene: Support for a Gatekeeper Mechanism in Skin Tumorigenesis”, Cancer Research 57, 4677-4681, Nov. 1, 1971.
Keeler, Richard F., “Teratogenic Effects of Cyclopamine and Jervine in Rats, Mice and Hamsters,” Proceedings of the Society for Experimantal Biology and Medicine, vol. 149, pp. 302-306 (1975) Copyright © 1975 by the Society for Experimental Biology and Medicine.
Maesawa, Chihaya et al, “Mutations in the Human Homologue of the Drosophila Patched Gene inEsophageal SquamousCell Carsinoma”, Genes, Chromosones & Cancer 21:276-279, (1998).
Omnell, M.L. et al., “Expression of Veratrum Alkaloid Teratogenicity in the Mouse,” Teratology, vol. 105-119 (1990).
Talpale Jussi et al., “Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine,” Nature, vol. 406, pp. 1005-1009 (Aug. 31, 2000) © 2000 Macmillan Magazines Ltd.
Xie, Jingwa et al, “Mutations of the Patched Gene in Several Types of SPoradic Extracutaneous Tumors”, Cancer Research 57, pp. 2369-2372, Jun. 15, 1997.
Michimukai, Eiji et al., “Mutations in the Human Homologue of theDrosophilaSegment Polarity Gene Patched in Oral Squamous Cell Carcinoma Cell Lines,” in Vitro Cellular & Developmental Biology, vol. 37, No. 7, pp. 459-464 (Jul./Aug. 2001) ProQuest Medical Library.
Berman, David M. et al., “Medulloblastoma Growth Inhibition by Hedgehog Pathway Blockade,” Science, vol. 297, pp. 1559-1561 (Aug. 30, 2002).
Watkins, D. Neil et al., “Hedgehog signaling within airway epithelial progenitors and in small-cell lung cancer,” Nature, vol. 422
Avci Oktay
Tas Sinan
Anderson James D
Marschel Ardin
Tas Sinan
LandOfFree
Pharmaceutical composition comprising a corticosteroid and a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition comprising a corticosteroid and a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition comprising a corticosteroid and a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4136794